Multidrug-Resistant Tuberculosis Not Due to Noncompliance but to Between-Patient Pharmacokinetic Variability

Garner, 2003, Directly observed treatment for tuberculosis, BMJ, 327, 823, 10.1136/bmj.327.7419.823

China Tuberculosis Control Collaboration, 2004, The effect of tuberculosis control in China, Lancet, 364, 417, 10.1016/S0140-6736(04)16764-0

Burman, 1997, Noncompliance with directly observed therapy for tuberculosis. Epidemiology and effect on the outcome of treatment, Chest, 111, 1168, 10.1378/chest.111.5.1168

Volmink, 2007, Directly observed therapy for treating tuberculosis, Cochrane Database Syst Rev, 4, CD003343

Calver, 2010, Emergence of increased resistance and extensively drug-resistant tuberculosis despite treatment adherence, South Africa, Emerg Infect Dis, 16, 264, 10.3201/eid1602.090968

Gumbo, 2007, Isoniazid's bactericidal activity ceases because of the emergence of resistance, not depletion of Mycobacterium tuberculosis in the log phase of growth, J Infect Dis, 195, 194, 10.1086/510247

Gumbo, 2007, Isoniazid bactericidal activity and resistance emergence: integrating pharmacodynamics and pharmacogenomics to predict efficacy in different ethnic populations, Antimicrob Agents Chemother, 51, 2329, 10.1128/AAC.00185-07

Gumbo, 2007, Concentration-dependent Mycobacterium tuberculosis killing and prevention of resistance by rifampin, Antimicrob Agents Chemother, 51, 3781, 10.1128/AAC.01533-06

Gumbo, 2009, Pharmacokinetics-pharmacodynamics of pyrazinamide in a novel in vitro model of tuberculosis for sterilizing effect: a paradigm for faster assessment of new antituberculosis drugs, Antimicrob Agents Chemother, 53, 3197, 10.1128/AAC.01681-08

Mitchison, 1985, The action of antituberculosis drugs in short-course chemotherapy, Tubercle, 66, 219, 10.1016/0041-3879(85)90040-6

Blumberg, 2003, American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America: treatment of tuberculosis, Am J Respir Crit Care Med, 167, 603, 10.1164/rccm.167.4.603

World Health Organization, 2010, Treatment of tuberculosis: guidelines, 4th ed

D'Argenio, 2009, ADAPT 5 user's guide: pharmacokinetic/pharmacodynamic systems analysis software

Gumbo, 2010, New susceptibility breakpoints for first-line antituberculosis drugs based on antimicrobial pharmacokinetic/pharmacodynamic science and population pharmacokinetic variability, Antimicrob Agents Chemother, 54, 1484, 10.1128/AAC.01474-09

Gonzalez, 1990, Evolution of the P450 gene superfamily: animal-plant ‘warfare', molecular drive and human genetic differences in drug oxidation, Trends Genet, 6, 182, 10.1016/0168-9525(90)90174-5

Wilkins, 2006, Variability in the population pharmacokinetics of pyrazinamide in South African tuberculosis patients, Eur J Clin Pharmacol, 62, 727, 10.1007/s00228-006-0141-z

Wilkins, 2008, Population pharmacokinetics of rifampin in pulmonary tuberculosis patients, including a semimechanistic model to describe variable absorption, Antimicrob Agents Chemother, 52, 2138, 10.1128/AAC.00461-07

Wilkins, 2011, Variability in the population pharmacokinetics of isoniazid in South African tuberculosis patients, Br J Clin Pharmacol, 72, 51, 10.1111/j.1365-2125.2011.03940.x

Selkon, 1964, The emergence of isoniazid-resistant cultures in patients with pulmonary tuberculosis during treatment with isoniazid alone or isoniazid plus PAS, Bull World Health Organ, 31, 294

Yeager, 1952, Pyrazinamide (aldinamide) in the treatment of pulmonary tuberculosis, Am Rev Tuberc, 65, 523

Vall-Spinosa, 1970, Rifampin in the treatment of drug-resistant Mycobacterium tuberculosis infections, N Engl J Med, 283, 616, 10.1056/NEJM197009172831202

Pasipanodya, 2010, Clinical and toxicodynamic evidence that high-dose pyrazinamide is not more hepatotoxic than the low doses currently used, Antimicrob Agents Chemother, 54, 2847, 10.1128/AAC.01567-09

Donald, 2007, The influence of dose and N-acetyltransferase-2 (NAT2) genotype and phenotype on the pharmacokinetics and pharmacodynamics of isoniazid, Eur J Clin Pharmacol, 63, 633, 10.1007/s00228-007-0305-5

Diacon, 2007, Early bactericidal activity of high-dose rifampin in patients with pulmonary tuberculosis evidenced by positive sputum smears, Antimicrob Agents Chemother, 51, 2994, 10.1128/AAC.01474-06

Sirgel, 2000, A multicentre study of the early bactericidal activity of anti-tuberculosis drugs, J Antimicrob Chemother, 45, 859, 10.1093/jac/45.6.859

Jindani, 1980, The early bactericidal activity of drugs in patients with pulmonary tuberculosis, Am Rev Respir Dis, 121, 939

McDermott, 1954, Activation of pyrazinamide and nicotinamide in acidic environments in vitro, Am Rev Tuberc, 70, 748

Yajko, 1995, Quantitative culture of Mycobacterium tuberculosis from clinical sputum specimens and dilution endpoint of its detection by the Amplicor PCR assay, J Clin Microbiol, 33, 1944, 10.1128/JCM.33.7.1944-1947.1995

Gangadharam, 1961, Rate of inactivation of isoniazid in South Indian patients with pulmonary tuberculosis. 3. Serum concentrations of isoniazid produced by three regimens of isoniazid alone and one of isoniazid plus PAS, Bull World Health Organ, 25, 793

David, 1970, Probability distribution of drug-resistant mutants in unselected populations of Mycobacterium tuberculosis, Appl Microbiol, 20, 810, 10.1128/AEM.20.5.810-814.1970

Gill, 2009, A replication clock for Mycobacterium tuberculosis, Nat Med, 15, 211, 10.1038/nm.1915

Gagneux, 2009, Fitness cost of drug resistance in Mycobacterium tuberculosis, Clin Microbiol Infect, 15, 66, 10.1111/j.1469-0691.2008.02685.x

Brindle, 2001, Serial counts of Mycobacterium tuberculosis in sputum as surrogate markers of the sterilising activity of rifampicin and pyrazinamide in treating pulmonary tuberculosis, BMC Pulm Med, 1, 2, 10.1186/1471-2466-1-2

Hesseling, 2010, Baseline sputum time to detection predicts month two culture conversion and relapse in non-HIV-infected patients, Int J Tuberc Lung Dis, 14, 560

Visser, 2011, The effect of vitamin A and zinc supplementation on treatment outcomes in pulmonary tuberculosis: a randomized controlled trial, Am J Clin Nutr, 93, 93, 10.3945/ajcn.110.001784

Vernon, 1999, Acquired rifamycin monoresistance in patients with HIV-related tuberculosis treated with once-weekly rifapentine and isoniazid. Tuberculosis Trials Consortium, Lancet, 353, 1843, 10.1016/S0140-6736(98)11467-8

Zhang, 2002, Conditions that may affect the results of susceptibility testing of Mycobacterium tuberculosis to pyrazinamide, J Med Microbiol, 51, 42, 10.1099/0022-1317-51-1-42

Zhang, 2003, The curious characteristics of pyrazinamide: a review, Int J Tuberc Lung Dis, 7, 6

Heifets, 1990, Is pyrazinamide bactericidal against Mycobacterium tuberculosis?, Am Rev Respir Dis, 141, 250, 10.1164/ajrccm/141.1.250

Pasipanodya, 2011, An oracle: antituberculosis pharmacokinetics-pharmacodynamics, clinical correlation, and clinical trial simulations to predict the future, Antimicrob Agents Chemother, 55, 24, 10.1128/AAC.00749-10